Gba Targeting Therapies is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides detailed information on this topic. See the content below for detailed information.
GBA (Glucocerebrosidase) gene variants are among the most significant genetic risk factors for Parkinson's disease. GBA encodes a lysosomal enzyme that degrades glucosylceramide, and mutations lead to reduced enzyme activity, lipid accumulation, and impaired autophagy. GBA-targeted therapies aim to enhance enzyme activity or reduce substrate accumulation.
Glucocerebrosidase (GCase) is a lysosomal enzyme encoded by the GBA gene that hydrolyzes glucosylceramide to ceramide and glucose. Loss of GCase function leads to:
| Agent | Type | Company | Development Status |
|---|---|---|---|
| Taliglucerase alfa (Elelyso) | Recombinant GCase | Pfizer | Approved for Gaucher's, PD trials |
| Velaglucerase alfa (VPRIV) | Recombinant GCase | Takeda | Approved for Gaucher's, PD trials |
| Imiglucerase (Cerezyme) | Recombinant GCase | Sanofi | Approved for Gaucher's, PD trials |
| Pegunigalsidase alfa | PEGylated GCase | Protalix | Phase I/II |
Small molecules that stabilize mutant GCase and promote proper folding.
| Compound | Company | Mechanism | Development Status |
|---|---|---|---|
| Migalastat (Galafold) | Amicus | Pharmacological chaperone | Approved for Fabry's, Phase II for PD |
| NCN-1 (Isofagomine) | -- | Pharmacological chaperone | Preclinical |
| GZ/SAR402671 | Sanofi | Pharmacological chaperone | Phase I/II |
| AT2101 (Afegostat) | Amicus | Pharmacological chaperone | Phase I/II |
| PYCR2 | -- | P5C reductase activator | Preclinical |
Reduce the substrate of GCase to compensate for reduced enzyme activity.
| Compound | Company | Mechanism | Status |
|---|---|---|---|
| Eliglustat (Cerdelga) | Sanofi | GCS inhibitor | Approved for Gaucher's |
| Venglustat (GZ161) | Sanofi | GCS inhibitor | Phase II for PD |
| Lucerastat (NCT02947087) | Idorsia | GCS inhibitor | Phase II |
Gene therapy approaches to increase GBA expression.
| Approach | Vector | Target | Company | Status |
|---|---|---|---|---|
| AAV2/9-GBA | Gene addition | CNS GBA | Various | Preclinical |
| CRISPR-Edited Cells | Gene editing | Autologous cells | Various | Preclinical |
| Trial | Intervention | Phase | Population | Status |
|---|---|---|---|---|
| MOVES-PD | Venglustat | Phase II | Early PD with GBA mutations | Recruiting |
| TEDY | Taliglucerase | Phase II | PD with GBA mutations | Ongoing |
| Trial | Intervention | Findings |
|---|---|---|
| Phase I | Taliglucerase | Safe, well-tolerated |
| Phase I | Eliglustat | Good CNS penetration |
The study of Gba Targeting Therapies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See also: Therapeutic Targets Index